The generic drug segment, a key driver of Amneal’s business, has shown particularly impressive growth. Analysts project a 17% growth for the generic segment in the third quarter of 2024 ...

Longer-term, Amneal has announced a partnership with Metsera, a clinical stage biotech developing a variety of different GLP-1 agonist drug candidates. According to Amneal's 2024 annual report ...

Amneal Pharmaceuticals (AMRX) is experiencing significant financial growth by focusing on making generic drugs more affordable and accessible—a ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.74 billion, has been making significant strides in the pharmaceutical ...

(Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, and mAbxience ("mAbxience") today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going to take a look at where Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ...

You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Amneal is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Ocular ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going to take a look at where Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) stands ...